Edgewise Therapeutics Inc

EWTX is in a Stage 4 Decline with a medium-term bearish bias reinforced by a terminal Blow-Off Top pattern and downtrending EMAs acting as resistance. Short-term conditions show price rejecting at the 9/21 EMA zone, favoring selling now into this resistance area.

• ↑$1.55B upfront from Servier acquisition funds cardiovascular R&D
• ↑EDG-7500 moved into Phase 3 after strong Phase 2 results
• ↓Lack of profitability shows struggles to generate efficient returns